Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Protagonist Therapeutics Inc shares valued at $237,000 were sold by Waddill William D. on Aug 27 ’25. At $59.25 per share, Waddill William D. sold 4,000 shares. The insider’s holdings dropped to 9,130 shares worth approximately $0.54 million following the completion of this transaction.
Also, WILLIAM WADDILL purchased 4,000 shares, netting a total of over 227,960 in proceeds.
Before that, PATEL DINESH V PH D had sold 10,415 shares from its account. In a trade valued at $570,534, the President and CEO traded Protagonist Therapeutics Inc shares for $54.78 each. Upon closing the transaction, the insider’s holdings decreased to 10,415 shares, worth approximately $30.83 million.
As published in their initiating research note from Barclays on September 17, 2025, Protagonist Therapeutics Inc [PTGX] has been an Overweight and the price target has been revised to $72. Analysts at Leerink Partners started covering the stock with ‘”an Outperform”‘ outlook in a report released in mid September. As of June 17, 2025, Citigroup has initiated its “Buy” rating for PTGX. Earlier on December 06, 2024, Goldman initiated its rating. Their recommendation was “a Neutral” for PTGX stock.
Analyzing PTGX Stock Performance
On last trading session, Protagonist Therapeutics Inc [NASDAQ: PTGX] rose 1.08% to $59.22. The stock’s lowest price that day was $59.05, but it reached a high of $61.335 in the same session. During the last five days, there has been a surge of approximately 2.56%. Over the course of the year, Protagonist Therapeutics Inc shares have jumped approximately 25.95%.
Is Protagonist Therapeutics Inc subject to short interest?
Stocks of Protagonist Therapeutics Inc saw a sharp rise in short interest on 2025-08-29 jumping by 1.09 million shares to 6.85 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 5.76 million shares. A jump of 15.91% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 10.47 of the overall float, the days-to-cover ratio (short ratio) jumped to 10.47.
Which companies own the most shares of Protagonist Therapeutics Inc (PTGX)?
In terms of Protagonist Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 70 in the next 12 months, up nearly 19.47% from the previous closing price of $58.59. Analysts anticipate Protagonist Therapeutics Inc stock to reach 76 by 2025, with the lowest price target being 50. In spite of this, 4 analysts ranked Protagonist Therapeutics Inc stock as Buy at the end of 2025. On December 06, 2024, BMO Capital Markets assigned a price target of “an Outperform” to the stock and initiated coverage with a $62.
